{
    "organizations": [],
    "uuid": "ce65bbd43f208fc590b07cef7d669c318ecd0474",
    "author": "",
    "url": "https://www.reuters.com/article/brief-novartis-amgen-announce-fda-approv/brief-novartis-amgen-announce-fda-approval-of-aimovig-treatment-for-migraine-prevention-idUSASC0A2VT",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention - Reuters",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 17 (Reuters) - Novartis Ag:\n* NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIGâ„¢ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION\n* EMA MARKETING AUTHORIZATION APPLICATION FOR AIMOVIG IS UNDER REVIEW. NOVARTIS EXPECTS APPROVAL IN EU IN COMING MONTHS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-18T02:44:00.000+03:00",
    "crawled": "2018-05-18T03:06:41.020+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "novartis",
        "ag",
        "novartis",
        "amgen",
        "announce",
        "fda",
        "approval",
        "novel",
        "treatment",
        "developed",
        "specifically",
        "migraine",
        "prevention",
        "ema",
        "marketing",
        "authorization",
        "application",
        "aimovig",
        "review",
        "novartis",
        "expects",
        "approval",
        "eu",
        "coming",
        "month",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}